In the company’s news yesterday,
Monogram Biosciences, Inc. announced presentations made by its scientists related to the company’s VeraTag™ assays. The presentations were made at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
The presentations dealt with EGFR/HER receptors, known to be significant to the proliferation of many different cancers, such as breast cancer. The presentations were about Monogram’s developments in the field of assays used for detecting these receptors in cancerous tissues, information that is critical for associated drug development and treatment regimens. The first presentation outlined the development of sensitive and specific assays in fixed tumor cell lines. The second presentation described the validation of these assays as providing quantitative and accurate measurements in human tumor tissue.
William Young, Monogram CEO, said “HERmark™, our recently launched breast cancer assay, is bringing new options to breast cancer patients with quantitative measurements of HER2 total protein and HER2:HER2 homodimer. This week’s presentations in Geneva evidence Monogram’s expanding portfolio of assays and the growing reach of the VeraTag technology.”
Gordon Parry, Ph.D., Monogram’s VP of Oncology R&D, added, “With our VeraTag platform, we can make precise and quantitative measurements of protein complexes that have not previously been possible. The data presented this week, on the HER1 and HER3 total protein assays, the HER1:HER1 homodimer assay and the activated HER1:HER2 heterodimer assay, provide support for the use of these assays in drug development programs not only in breast cancer, our current focus, but also in other cancer types.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
